Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TTPH
2551
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $1.02M | ﹤0.01% |
7,184
-50
| -0.7% | -$7.73K |
|
2552
Banner Corp
BANR
$2.5B
| $1.02M | ﹤0.01% |
17,999
-84,670
| -82% | -$4.66M |
|
|
CDTX
2553
DELISTED
Cidara Therapeutics
CDTX
| $1.02M | ﹤0.01% |
6,775
+5,000
| +282% | +$691K |
|
|
IO
2554
DELISTED
ION Geophysical Corporation
IO
| $1.01M | ﹤0.01% |
232,782
-200
| -0.1% | -$875 |
|
2555
Fate Therapeutics
FATE
$294M
| $1M | ﹤0.01% |
308,800
+13,100
| +4% | +$50.2K |
|
|
KSPN
2556
DELISTED
Kaspien Holdings Inc. Common Stock
KSPN
| $997K | ﹤0.01% |
31,150
+360
| +1% | +$12.6K |
|
2557
Shutterstock
SSTK
$217M
| $996K | ﹤0.01% |
22,600
-203,700
| -90% | -$9.01M |
|
|
DVCR
2558
DELISTED
Diversicare Healthcare Services Inc
DVCR
| $993K | ﹤0.01% |
106,800
+600
| +0.6% | +$6.09K |
|
2559
AAR Corp
AIR
$5.96B
| $986K | ﹤0.01% |
+28,360
| New | +$984K |
|
2560
Outfront Media
OUT
$5.29B
| $985K | ﹤0.01% |
43,281
-11,175
| -21% | -$265K |
|
|
BBQ
2561
DELISTED
BBQ Holdings, Inc. Common Stock
BBQ
| $984K | ﹤0.01% |
273,400
-20,600
| -7% | -$80.4K |
|
2562
Omega Flex
OFLX
$304M
| $979K | ﹤0.01% |
15,200
+4,000
| +36% | +$231K |
|
2563
Matrix Service
MTRX
$330M
| $976K | ﹤0.01% |
+104,426
| New | +$1.17M |
|
|
CGNT
2564
DELISTED
Cogentix Medical, Inc.
CGNT
| $973K | ﹤0.01% |
559,079
-3,917
| -0.7% | -$6.72K |
|
|
RBS.PRF.CL
2565
DELISTED
Royal Bk Of Scotland Gp
RBS.PRF.CL
| $966K | ﹤0.01% |
35,961
-7,262
| -17% | -$193K |
|
2566
Cineverse
CNVS
$68.2M
| $965K | ﹤0.01% |
27,717
+6,165
| +29% | +$207K |
|
2567
CPI Card Group
PMTS
$341M
| $960K | ﹤0.01% |
67,360
+6,200
| +10% | +$88.5K |
|
2568
Duluth Holdings
DLTH
$151M
| $956K | ﹤0.01% |
+52,516
| New | +$1.04M |
|
|
BRT
2569
BRT Apartments
BRT
$268M
| $950K | ﹤0.01% |
120,860
+12,600
| +12% | +$101K |
|
|
ABTX
2570
DELISTED
Allegiance Bancshares
ABTX
| $946K | ﹤0.01% |
+24,700
| New | +$949K |
|
2571
Rapid7
RPD
$929M
| $944K | ﹤0.01% |
+56,100
| New | +$968K |
|
|
SIRE
2572
DELISTED
Sisecam Resources LP
SIRE
| $942K | ﹤0.01% |
34,372
-13,563
| -28% | -$383K |
|
|
ANCB
2573
DELISTED
Anchor Bancorp
ANCB
| $942K | ﹤0.01% |
37,599
+14,199
| +61% | +$356K |
|
|
IHC
2574
DELISTED
Independence Holding Company
IHC
| $941K | ﹤0.01% |
46,000
+14,100
| +44% | +$269K |
|
|
AFH
2575
DELISTED
Atlas Financial Holdings, Inc. Ordinary Shares
AFH
| $940K | ﹤0.01% |
63,100
-11,900
| -16% | -$168K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.